menu ☰
menu ˟

Padlock Therapeutics enters into agreement with GSK to target autoimmune diseases

29 May 2015
Padlock Therapeutics announced it has entered into an agreement with GSK to license a collection of assets and intellectual property from GSK intended to develop treatments for autoimmune diseases, including rheumatoid arthritis, systemic lupus eryth...

Click here to view the full article which appeared in Rheumatology

IPH Logo